Abiopharma

🔍 Weigand Matthew Robert (Director)

Company: Nebius Group N.V. (NBIS)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Acquired 1,352 shares of Class A Shares (Direct)
  Date: 2026-09-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 14,987.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Represents restricted share units ("RSUs") granted on September 1, 2026 under the Company's Amended and Restated Equity Incentive Plan, as amended on August 15, 2024. The RSUs vest in full on January 2, 2027. Each RSU represents a right to receive one Class A Share of Nebius upon vesting.
• F2: These holdings have been updated to reflect 9,102 Class A Shares of Nebius that have been distributed by various Accel-affiliated funds, in each case to the limited partners or members of the distributing entity for no consideration, representing each limited partner's or member's pro-rata interest in such shares in accordance with the exemptions afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
• REMARKS: Exhibit 24 - Power of Attorney; Due to the issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Act, the reporting person's transactions in the issuer's equity securities are exempt from Sections 16(b) and 16(c) of the Act.